跳至主要内容
临床试验/NCT06003127
NCT06003127招募中不适用

REcovery From DEXmedetomidine-induced Unconsciousness

Massachusetts General Hospital2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2024年11月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
12
试验地点
2
主要终点
Time to return of responsiveness

研究概览

简要总结

This pilot study in healthy volunteers aims to determine if biological sex has an impact on recovery from dexmedetomidine-induced unconsciousness, and if transcranial magnetic stimulation combined with electroencephalography (TMS-EEG) can be used to measure brain complexity during dexmedetomidine sedation without arousing study participants.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Between the ages of 18 to 65
  • Normal body weight and habitus, body mass index (BMI) 18 to 30 kg/m2
  • Non-smoker
  • No history of taking stimulants or substance abuse
  • For women: either use of hormonal contraception, or > 45 years old and last menstrual period > 12 months ago in the absence of any contraceptives.
  • American Society of Anesthesiologists (ASA) physical status classification 1 (ASA 1)
  • Fluent in English (sufficient to communicate with the study team and understand the consent form)

排除标准

  • Neurologic: epilepsy or positive history of a seizure, stroke, central disorders of hypersomnolence, neuroimmunological disorder (e.g. multiple sclerosis), Meniere's disease, Parkinson's disease, peripheral neuropathy, no significant visual or hearing impairments, findings in the clinical examination suggesting a neurologic disorder
  • Psychiatric: history or treatment for an active psychiatric problem (including Attention-Deficit / Hyperactivity Disorder (ADHD) and anxiety disorder)
  • Cardiovascular: hypertension, symptomatic hypotension or bradycardia, myocardial infarction, coronary artery disease, peripheral vascular disease, dysrhythmias, congestive heart failure, cardiomyopathy, valvular disease, familial history of sudden cardiac death
  • Respiratory: bronchitis, asthma, chronic obstructive pulmonary disease, smoking, shortness of breath, sleep apnea
  • Gastrointestinal: esophageal reflux, hiatal hernia, ulcer
  • Hepatic: hepatitis, jaundice, ascites
  • Renal: acute or chronic severe renal insufficiency
  • Reproductive: pregnancy, breast-feeding
  • Endocrine: diabetes, thyroid disease, adrenal gland disease
  • Hematologic: blood dyscrasias, anemia, coagulopathies
  • Musculoskeletal: prior surgery or trauma to head neck or face, arthritis, personal or family history of malignant hyperthermia
  • Medications: regular use of prescription and non-prescription medications expected to affect central nervous function, anticoagulant or thrombocyte-aggregation inhibiting therapy; exception: oral hormonal contraception
  • Allergies: dexmedetomidine, phenylephrine, betablockers (including labetalol and esmolol), hydralazine, glycopyrrolate
  • Potential participants will not be enrolled in our study if they fail to pass a standard drug screening test (toxicology).

结局指标

主要结局

Time to return of responsiveness

时间窗: Up to 120 minutes

The time to return of responsiveness will be measured in minutes and from the moment of dexmedetomidine discontinuation to the return of clicking a button in response to auditory stimulation.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Emery Brown

Professor of Anesthesia

Massachusetts General Hospital

研究点 (2)

Loading locations...

相似试验